| DB ID | MyCo_2761 |
| Title | Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study |
| Year | 2016 |
| PMID | 27393123 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | Haematology patients |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study was registered at ClinicalTrials.gov (identifier NCT01695512). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | Clinical samples (BAL, peripheral blood) from a total of 99 immunocompromised patients were processed for diagnostic purposes after obtaining informed consent. The study population consisted of individuals with underlying hematological diseases (95% (94/99)) or with severe prolonged myelo- and immunosuppression due to therapeutic regimens (5% (5/99)) and therefore high probability for fungal infections. Patients were classified as proven (n=3), probable (n=34), possible (n=33) and no IFD (n=29) according to EORTC/MSG 2008 consensus criteria. Another subgroup of patients with proven/probable aspergillosis was defined by culture, microscopic and positive GM results (n=20). |
| Cohort No. | 99 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive fungal disease (IFD), particularly invasive aspergillosis (IA) represents life- threatening complications in patients with hematological malignancies receiving intensive chemotherapy or undergoing allogeneic hematopoietic stem cell transplantation. Early diagnosis is associated with improved survival. Antifungal therapy (AFT) is usually started empirically or pre-emptively, based on host factors, fever or a chest CT-driven approach. |
| Technique | ELISA |
| Analysis Method | ELISA Based, Aspergillus PCR |
| ELISA kits | PlateliaTM Aspergillus EIA assay (Bio-Rad, Munich, Germany) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | ELISA Based, Aspergillus PCR, FDA approved Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
